Journal of Physiology & Pathology in Korean Medicine (동의생리병리학회지)

The Physiological Society of Korean Medicine and The Society of Pathology in Korean Medicine (대한동의생리학회·한의병리학회)
권호 표지

New Prognostic Significance of Malignant Pleural Effusion In Patients with Non-Small Cell Lung Cancer

비소세포폐암의 예후 결정에 있어 악성 흉수의 새로운 의의

  • Kim, So-Young (Department of Internal Medicine, Wonkwang University) ;
  • Park, Seong-Hoon (Department of Radiology, Wonkwang University) ;
  • Shin, Jeong-Hyun (Department of Internal Medicine, Wonkwang University) ;
  • Shin, Seong-Nam (Department of Internal Medicine, Wonkwang University) ;
  • Kim, Dong (Department of Internal Medicine, Wonkwang University) ;
  • Lee, Mi-Kung (Department of Thoracic Surgery, Wonkwang University) ;
  • Lee, Sam-Youn (Department of Thoracic Surgery, Wonkwang University) ;
  • Choi, Soon-Ho (Department of Thoracic Surgery, Wonkwang University) ;
  • Kim, Hak-Ryul (Department of Internal Medicine, Wonkwang University) ;
  • Jeong, Eun-Taik (Department of Internal Medicine, Wonkwang University) ;
  • Moon, Sun-Rock (Department of Radiation Oncology, Wonkwang University) ;
  • Lee, Kang-Kyu (Department of Radiation Oncology, Wonkwang University) ;
  • Yang, Sei-Hoon (Department of Internal Medicine, Wonkwang University)
  • 김소영 (원광대학교 의과대학 내과) ;
  • 박성훈 (원광대학교 의과대학 영상의학과) ;
  • 신정현 (원광대학교 의과대학 내과) ;
  • 신성남 (원광대학교 의과대학 내과) ;
  • 김동 (원광대학교 의과대학 내과) ;
  • 이미경 (원광대학교 의과대학 흉부외과) ;
  • 이삼윤 (원광대학교 의과대학 흉부외과) ;
  • 최순호 (원광대학교 의과대학 흉부외과) ;
  • 김학렬 (원광대학교 의과대학 내과) ;
  • 정은택 (원광대학교 의과대학 내과) ;
  • 문성록 (원광대학교 의과대학 방사선종양학과) ;
  • 이강규 (원광대학교 의과대학 방사선종양학과) ;
  • 양세훈 (원광대학교 의과대학 내과)
  • Published : 2009.06.25
Download PDF
⟨ Previous Next ⟩

Abstract

Several studies showed that the survival rate of stage IIIB disease with malignant pleural effusion is worse than stage IIIB disease without malignant effusion. But, malignant pleural effusion was considered T4. To analyze changes the survival time for malignant pleural effusion, in the seventh revision of TNM classification for lung cancer. The records of all patients had to have either a histological or cytological diagnosis of non-small cell lung cancer (NSCLC), who were admitted to Wonkwang university hospital between January 2004 and December 2006 were reviewed retrospectively. We evaluated the survival time of 187 patients with advanced lung cancer with and without malignant pleural effusion. This included the pleural effusion or nodule M1 a (pleural dissemination, currently classified as T4), nodule(s) in the other lung M1 a (contralateral lung nodule, currently classified as M1), nodule(s) with the same lobe as the primary tumor T3 (currently classified as T4), other T4 factors T4 (T4 MO anyN), and extrathoracic sites of disease M1b (distant metastasis, currently classified M1). Among the 187 patients, T4anyNMO was 57 patients in the current TNM classification. In the next edition of the TNM classification, T4MOanyN-T4 (excluding same lobe nodules) was 12 patients, pleural dissemiantion-M1a was 45 patients, contralateral lung nodule(s)-M1a was 7 patients, and metastatic disease-M1b was 55 patients. We compared the survival time for these groups. Survival time was 11 months, 8 months, 11 months, and 4 months. The survival time of malignant pleural effusion was shorter than other T4 factors without pleural effusion. But, there was no remarkable difference in statistics due to small cases (p=0.23). We strongly suggest that malignant pleural effusion in advanced NSCLC will be categorized with metastatic disease.

Keywords

References

  1. Mountain, C.F. Revision in the international staging system for lung cancer. Chest 111: 1710-1717, 1997 https://doi.org/10.1378/chest.111.6.1710
  2. Sobin, L., Wittekind, C.h. (Eds.) TNM Classification of Malignant Tumours, 6th Ed. New York, Wiley-Liss, pp 99-103, 2002
  3. Leong, S.S., Rocha Lima, C.M., Sherman, C.A.. The 1997 International Staging System for non-small cell lung cancer: have all the issues been addressed?. Chest. 115: 242-248, 1999 https://doi.org/10.1378/chest.115.1.242
  4. Naruke, T., Tsuchiya, R., Kondo, H. Implications of staging in lung cancer. Chest. 112: 242S-248S, 1997 https://doi.org/10.1378/chest.112.4_Supplement.242S
  5. van de Molengraft, F.J., Vooijs, G.P. Survival of patients with malignancy-associated effusions. Acta Cytol. 33: 911-916, 1989
  6. Monte, S.A., Ehya, H., Lang, W.R. Positive effusion cytology as the initial presentation of malignancy. Acta Cytol. 31: 448-452, 1987
  7. Sears, D., Hajdu, S.I. The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions. Acta Cytol. 31: 85-97, 1987
  8. Mountain, C.F. A new international staging system for lung cancer. Chest. 89: 225S-233S, 1986 https://doi.org/10.1378/chest.89.4_Supplement.225S
  9. Postmus, P.E., Brambilla, E., Chansky, K. The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol. 2: 686-693, 2007 https://doi.org/10.1097/JTO.0b013e31811f4703
  10. Goldstraw, P., Crowley, J., Chansky, K. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2: 706-714, 2007 https://doi.org/10.1097/JTO.0b013e31812f3c1a
  11. Rusch, V.W., Crowley, J., Giroux, D.J. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2: 603-612, 2007 https://doi.org/10.1097/JTO.0b013e31807ec803
  12. Rami-Porta, R., Ball, D., Crowley, J. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2: 593-602, 2007 https://doi.org/10.1097/JTO.0b013e31807a2f81
  13. Pujol, J.L., Chakra, M. Staging metastasis profile of non-small cell lung cancer: a new paradigm? J Thorac Oncol. 2: 679-681, 2007 https://doi.org/10.1097/JTO.0b013e31812d05f4
  14. Socinski, M.A., Morris, D.E., Masters, G.A. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest. 123: 226S-243S, 2003 https://doi.org/10.1378/chest.123.1_suppl.226S
  15. Jett, J.R., Scott, W.J., Rivera, M.P. Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest. 123: 221S-225S, 2003 https://doi.org/10.1378/chest.123.1_suppl.221S
  16. Sugiura, S., Ando, Y., Hironobu, M. Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res. 3: 47-50, 1997
  17. Alon, B.N., Anson, B.L. Pleural effusion in patients with non-small cell carcinoma--stage IV and not T4. Lung Cancer. 57: 123, 2007 https://doi.org/10.1016/j.lungcan.2007.03.004
  18. Ou, S.H., Zell, J.A. Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California Cancer Registry. J Thorac Oncol. 3: 216-227, 2008 https://doi.org/10.1097/JTO.0b013e318164545d